B. Christopher Kim, Ph.D.
Dr. Kim is Founding Managing Partner of the Korea-Seoul Life Science Fund (KSLSF). He is responsible for all aspects of investment, portfolio support and Fund operations of KSLSF. Dr. Kim's investments include PharmAbcine (member of BOD, mAb therapies for cancer), Pathway Genomics (personalized genetic testing, San Diego), CrystalGenomics (KOSDAQ listed, small molecules to treat inflammation, infection and cancer).
Prior to joining OBP, Dr. Kim served as Associate Director and Head of Operations for the global BioMarker Development group at the Novartis Institutes for BioMedical Research. He held an additional role in corporate development and strategy while at Novartis. Previously, Dr. Kim was a member of the IBM Extreme Blue program, providing strategic direction for IBM Healthcare and Life Sciences. At Alkermes, he conducted preclinical pharmacology research to evaluate proprietary drug delivery systems. Throughout his career, Dr. Kim has been engaged by VC firms and biotech companies as their advisor or consultant. He is a Special Advisor of Extera Partners, a Cambridge-based investment bank specialized in life sciences transactions.
Dr. Kim received an MBA from Carnegie Mellon University where he was President of the BioPharma Business Club. Dr. Kim obtained a PhD in Biomedical Sciences from the University of Texas Health Science Center and the MD Anderson Cancer Center with a focus on developmental biology, and a BA in Economics and BS in Biology from the University of California at Irvine. Dr. Kim authored a number of peer-reviewed scientific publications in the areas of preclinical pharmacology, and developmental biology.
Back to OBP Team